Engflag

Carpaquin

Quick links to important sections

Carpaquin

Carpaquin_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Carpaquin

Property Description
Active ingredient Carprofen
Form Oral tablets (Caplets or Chewable)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Relief from pain and inflammation
Origin Synthetic, Propionic acid derivative

What Type of Medicine is Carpaquin? (Identity and Classification)

Carpaquin is a veterinary drug containing the active ingredient Carprofen, which is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This medication is a synthetic, non-narcotic agent designed for use exclusively in dogs, a key differentiating factor from human NSAIDs. Carprofen belongs to the Propionic acid class of compounds, a chemical grouping whose efficacy is widely recognized in pharmacological studies for its analgesic properties. The drug is exclusively available by veterinary prescription, which confirms its status as a controlled agent requiring professional clinical oversight.

Composition and Pharmaceutical Form of Carprofen Tablets

The foundation of Carpaquin is its single active ingredient, Carprofen (INN), which provides the therapeutic effect. Carpaquin is primarily supplied in an oral dosage form, typically as easily accepted chewable or caplet tablets. This dosage form is designed to enhance patient compliance, a crucial consideration for veterinary products. As a single-ingredient product, Carpaquin is formulated with various pharmaceutical excipients necessary to ensure tablet integrity, proper dissolution, and uptake upon oral administration, supporting its systemic effect.

General Purpose and High-Level Action

The general purpose of Carpaquin is to deliver targeted symptomatic relief from physical discomfort associated with inflammation. It functions as an analgesic and anti-inflammatory agent by modulating the body's response to pain, a use clinically recognized for this compound. This capability makes Carpaquin a common choice for managing general discomfort in active or older dogs. The high-level action is characterized by the targeted reduction of inflammation at a fundamental cellular level, helping to improve general physical comfort and maintain the patient’s desired level of mobility.

What side effects are possible with Carpaquin?

Possible side effects and safety information

The official safety profile for Carpaquin (Carprofen) is defined by documented adverse reactions primarily affecting the gastrointestinal system, though potential effects on the renal (kidney) and hepatic (liver) systems are also noted in regulatory labeling. The frequency of documented effects is often categorized based on data from controlled clinical studies.

Documented Adverse Reaction Categories

Side effects are classified by the physiological system affected, with the most frequently reported signs including vomiting, diarrhea, and decreased appetite (inappetence). Less common, but documented, effects include lethargy, changes in drinking and urination (polyuria/polydipsia), and various skin changes (e.g., pruritus, redness). Adverse reactions are systematically reported across the Gastrointestinal, Hepatic, Renal/Urinary, Neurologic, and Dermatologic system-organ classes.

Serious Adverse Reactions and Safety Constraints

The label defines a number of reactions as serious, including gastrointestinal ulceration and bleeding, acute hepatic toxicity, and acute renal failure. In rare situations, serious adverse reactions resulting in death have been reported in post-market surveillance.

Regulatory documents impose specific safety constraints. Co-administration with other NSAIDs or corticosteroids is to be avoided due to the documented potential for a severe increase in adverse reactions. Furthermore, the drug is not to be used in individuals with bleeding disorders or known allergy to Carprofen. Specific monitoring of liver and kidney values is often recommended two to four weeks after starting long-term therapy.

Population-Specific Safety Notes

The safety profile identifies patient groups at increased risk, particularly those who are dehydrated or have pre-existing renal, cardiovascular, or hepatic dysfunction. Caution is also recommended for use in senior patients, whose age may contribute to increased susceptibility to adverse effects.

Overdose and Emergency Response

The official regulatory profile for Carpaquin overdose is defined by the potential for severe systemic toxicity and mandatory emergency action. Documented overdose presentations primarily involve the gastrointestinal system, with common signs including vomiting, diarrhea, melena (black or tarry stools), and inappetence. Systemic toxicity may present with neurological signs like lethargy, seizures, and incoordination, or organ-related indicators such as jaundice, polydipsia, and polyuria.

The most serious outcomes described in regulatory documents are Acute Renal Failure, Acute Hepatic Toxicity, and Gastrointestinal ulceration and/or perforation. Death has been reported in rare, severe cases.

Immediate emergency action is explicitly mandated: if a suspected overdose or signs of drug intolerance are observed, stop giving the drug immediately and contact a veterinarian. The regulatory label also requires that in the event of accidental human ingestion of the tablets, immediate medical advice must be sought and the product labeling shown to the physician.

The official documents state that no specific antidote is known for Carprofen overdosage, confirming that management relies on general supportive therapy and continuous monitoring of renal, hepatic, and gastrointestinal function. The drug is explicitly not approved for use in cats due to species-specific susceptibility to toxicity.

Therapeutic Uses of Carpaquin

Carpaquin is used exclusively in dogs to provide symptomatic relief by moderating pain, reducing inflammation, and offering general anti-inflammatory support across key therapeutic domains. Its purpose is to provide support that helps ease the overall symptom burden, contributing to improved day-to-day comfort and physical function.

This medication is commonly used across conditions characterized by periods of heightened symptoms, such as chronic joint discomfort, primarily due to osteoarthritis and other degenerative joint diseases. Indications include the relief of pain and inflammation associated with osteoarthritis, as well as the control of acute postoperative pain following soft tissue and orthopedic surgeries. It is used for managing symptom clusters like stiffness, limping, and a reluctance to stand or move, providing support that may assist with maintaining functional stability and improved comfort during symptomatic periods.

“The primary goal is to provide supportive relief when symptoms interfere with routine activities, contributing to overall physical comfort during symptomatic phases.”

Quick Fact: Relief for Joint Discomfort

Primary Symptom Domain Key Benefit Use Context
Musculoskeletal Discomfort Assists with maintaining functional stability Conditions characterized by periods of heightened symptoms
Acute Swelling and Pain Contributes to easing the overall symptom load Postoperative periods and acute injury-related episodes
Symptoms related to systemic imbalance Contributes to improved comfort during symptomatic periods Relevant in contexts involving heightened systemic burden

Regulatory References

  1. FDA Center for Veterinary Medicine Client Information Sheet

Eligibility and Restrictions for Use

️ Official Eligibility Profile: Carpaquin (Carprofen)

The use of Carpaquin is governed by strict population-based rules defined in government regulatory documents.

Eligibility Scope

Classification Status/Population
Populations for whom use is allowed (as stated in label): Dogs (Canis familiaris)
Populations for whom use is not recommended (if applicable): Pregnant, lactating, or breeding dogs; dogs with bleeding disorders; aged dogs
Populations for whom use is contraindicated: Cats, Humans, Dogs with previous hypersensitivity to carprofen or other NSAIDs

Eligibility Criteria

Age-Related Eligibility Rules

  • Safety is not established in puppies under six weeks of age, with some regions setting the minimum threshold at 10 weeks of age.

Condition-Specific Eligibility Rules

  • The medicine is contraindicated in dogs suffering from pre-existing severe cardiac, hepatic, or renal disease, or those with potential for gastrointestinal ulceration or bleeding.

Eligibility-Related Restrictions

  • Use must be avoided in dogs that are dehydrated, hypovolemic, or hypotensive due to potential for increased renal toxicity.
  • Concurrent use with other anti-inflammatory drugs, such as corticosteroids, should be avoided.

Connection to the Overall Eligibility Profile

Official regulatory documents define Carpaquin's eligibility by establishing its use strictly in dogs. This profile is enforced through absolute contraindications (e.g., species, allergy) and restrictions for specific populations (e.g., young, breeding, or physiologically stressed animals), thereby defining all regulatory exclusion criteria for the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Carprofen, a Nonsteroidal Anti-inflammatory Drug (NSAID), primarily based on pharmacodynamic reinforcement and competition for plasma protein binding.

Contraindicated Combinations and Timing Rules

Co-administration with other NSAIDs is prohibited because of the potential for additive gastrointestinal and renal toxicity. Similarly, concurrent use with glucocorticoids (corticosteroids) is prohibited due to a significantly increased risk of gastrointestinal ulceration and hemorrhage.

A timing separation rule is mandatory: Carprofen must not be administered concurrently or within 24 hours of another NSAID or glucocorticoid.

Other Documented Interactions

Classification Interacting Entity Interaction Statement (Regulatory Basis)
Additive Nephrotoxicity Potentially Nephrotoxic Drugs (e.g., Diuretics, ACE Inhibitors) Increased risk of renal toxicity, especially in dehydrated or hypotensive patients.
Bleeding Risk Anticoagulants (e.g., Warfarin) Increased risk of bleeding and hemorrhage.
Exposure Modification Highly Protein-Bound Drugs Potential for competition at plasma protein binding sites, leading to increased drug exposure for both agents.

The official labeling states that Carprofen tablets may be administered with or without food, as food does not dictate a mandatory timing rule.

Mechanism of Action

Selective Inhibition of the COX-2 Enzyme System

Carpaquin's mechanism of action initiates with the active ingredient, Carprofen, acting as a reversible competitive inhibitor of the Cyclooxygenase (COX) enzymes, showing functional selectivity for the inducible COX-2 isoform. This targeted enzyme blockade interrupts the conversion of arachidonic acid into pro-inflammatory mediators, which is the foundational molecular step in the sequence leading to the observed physiological modulation.

Modulating the Prostaglandin Synthesis Cascade

By inhibiting COX-2 activity, Carprofen directly dampens the production of pain-sensitizing prostaglandins both at the peripheral site of tissue injury and centrally within the hypothalamus. This molecular intervention contributes to the decreased excitability of peripheral nociceptors (pain receptors) and modulates an elevated thermal set point. The drug's action is confined to the COX pathway and does not modulate the 5-Lipoxygenase (5-LOX) pathway, meaning the production of leukotrienes remains unaffected.

Dosage and Administration Information

How to Use Carpaquin

Carpaquin (Carprofen) is a veterinary medication whose administration is strictly governed by official regulatory protocols. The drug is restricted to use in dogs only, and its dispensing is limited to the order of a licensed veterinarian, confirming its required professional oversight.

Official Dosing and Administration

The medication is officially approved for two primary routes of administration: Oral (using tablets or chewable forms) and Subcutaneous (via injection) for clinical use. The standard recommended total daily dosage is calculated at 4.4 mg per kilogram of body weight (4.4 mg/kg/day), representing the maximum amount that should be administered daily.

This daily dose can be delivered using one of two approved schedules:

  • Once daily at the full 4.4 mg/kg dosage.
  • Divided twice daily into two equal doses of 2.2 mg/kg each.

Oral administration is permitted with or without food, providing flexibility in routine. Tablets are frequently scored to ensure accurate dose division, adhering to the weight-based dosing requirements.

Administration Contexts

Administration may be categorized as either short-term for acute pain control, such as post-operative management, or long-term for sustained conditions like chronic joint discomfort. Regulatory guidelines mandate particular caution when administering Carpaquin to very young dogs (under six weeks of age). For older patients, a reduced initial dosage may be required to accommodate potential physiological changes.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Carpaquin

Evidence for Use in Managing Pain and Inflammation Related to Osteoarthritis

Research for Carpaquin in the context of chronic joint discomfort, often associated with osteoarthritis, was evaluated in various study designs, including randomized controlled trials (RCTs) and clinical field studies. These studies focused on outcomes related to physical discomfort and daily functioning. Researchers monitored measurements like lameness scores and objective assessments such as specialized gait analysis.

The studies described patterns where measured lameness and mobility scores were reported during the use of the compound. Assessments by veterinarians and owners frequently reported the measured parameters of physical comfort and functional stability in the patient populations studied. Evidence for direct comparison against all other anti-inflammatory options is limited. Furthermore, sample sizes were modest in some head-to-head trials, meaning results apply only to the populations studied and research does not determine whether an individual will respond similarly.

Evidence for Use in Controlling Acute Postoperative Pain

Carpaquin was studied for research exploring its use in the context of discomfort and inflammation immediately following common surgeries. The research was evaluated in randomized, masked trials where the primary outcomes describing episodic or acute changes were tracked using specialized pain scoring systems and by monitoring the amount of additional analgesic medication needed post-surgery.

Research highlights changes measured during the study period where data show patterns where measured pain scores were observed in those receiving the compound compared to controls. The available research provides context, but follow-up durations were limited, focusing mainly on the first 72 hours post-surgery. Therefore, there is limited information for long-term outcomes or how the acute use may affect the recovery phases beyond the immediate post-operative period.

Understanding the Strength and Limitations of the Evidence

The body of research describes what has been observed so far for the two main areas of use. However, the evidence quality varies across studies, leading to an overall grading of Moderate for both indications. A key limitation is the reliance on subjective measures, such as patient-reported outcomes describing perceived discomfort; results were subject to variability.

Key Studies & References

  1. Rimadyl (carprofen) package insert and client information sheet - Animal Drugs @ FDA
  2. Novox (carprofen) package insert and client information sheet - Animal Drugs @ FDA

Frequently Asked Questions (FAQ)

Common questions about Carpaquin (FAQ)

Q: What is the main use of Carpaquin?

Regulatory documents state that Carpaquin is indicated for the treatment of mild to moderate chronic pain. This type of pain is typically associated with various musculoskeletal conditions in adults. Official product information confirms its purpose as a management option for this specific chronic discomfort.

Q: How long does it take for Carpaquin to start working?

According to the official product information, pain relief is generally expected to begin relatively quickly after a dose. Clinical studies indicate that the onset of action, which is when the medication starts working, is typically within 30 to 60 minutes. Individual results may vary based on personal factors.

Q: Can I take Carpaquin with food?

Official information indicates that taking Carpaquin with food or milk is an option. The product label suggests that this may help to reduce the potential for stomach upset or gastrointestinal irritation. This is a common practice for medications that can affect the digestive system.

Q: What should I do if I miss a dose?

Official guidelines provide directions to take the missed dose of Carpaquin as soon as it's remembered. The guidance is to skip the dose if it is close to the scheduled time for the next dose. Official information advises against taking two doses close together or doubling the dose.

Q: Does Carpaquin interact with common pain relievers like ibuprofen?

The regulatory product label cautions against taking Carpaquin with other medicines known as NSAIDs (non-steroidal anti-inflammatory drugs), such as ibuprofen. Official information indicates that combining these medications increases the risk of serious side effects. This warning is due to the potential for similar drug mechanisms to lead to harm.

Q: Is Carpaquin a narcotic or opioid drug?

According to the official product information, Carpaquin is not a narcotic drug, nor is it classified as an opioid. It is specifically defined as a non-steroidal anti-inflammatory drug (NSAID). This means it works through reducing inflammation and is in a distinct drug class from controlled substances.

Q: Can Carpaquin cause drowsiness?

Yes, official safety information lists both dizziness and drowsiness as possible side effects, though they are generally considered uncommon. According to regulatory sources, this is a known, non-frequent effect associated with the medicine. Patients should be aware of this potential response.

How should Carpaquin be stored and disposed of?

How to Store and Dispose of Carpaquin

Carpaquin (carprofen) tablets must be stored at controlled room temperature, maintaining a specific range between 59 F and 86 F (15 C and 30 C). The medication must be protected from excessive heat and moisture to preserve its stability.

Container and Safety

To prevent accidental ingestion and maintain product integrity, the tablets must be kept in their tightly closed original container. It is a mandatory requirement to store the container securely, out of the reach of children and all pets, as stated in the regulatory labeling.

️ Disposal Requirements

Disposal of unused or expired Carpaquin should prioritize safe methods, such as utilizing a drug take-back program. If a take-back program is unavailable, the product must be mixed with an unpalatable substance (like kitty litter) in a sealed bag before being discarded with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Carpaquin found in:

A-Z Index: